


ETCTN Trials by Disease/Treatment Area: Solid Tumors with Specific Mutations



NOTE: ▼ Limited trial; not open ETCTN-wide

## ETCTN Solid Tumors with Specific Mutations Trials (Open as of 4/15/2026)

<b>Protocol Number</b>	<b>Phase</b>	<b>Protocol Title</b>
<b>10355</b>	I	A Phase I Study of DS-8201a in Combination with Olaparib in HER2-Expressing Malignancies
<b>10371</b>	II	A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients with Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response
<b>10528</b>	I	Phase 1 study of the POLq inhibitor Novobiocin in BRCA-mutant and other DNA damage repair-deficient solid tumors
<b>10527</b>	Ib	A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination with the ATR Inhibitor M1774
<b>10572</b>	I	A Phase 1 Trial Evaluating the Combination of Temozolomide and the Ataxia Telangiectasia and Rad3-Related Inhibitor M1774
<b>10495</b>	I	Phase I Trial of DS-8201a (Trastuzumab Deruxtecan) in Combination with Neratinib in Solid Tumors with HER2 Alterations
<b>10358</b>	I/Ib	Phase 1/1B Study of DS-8201a in Combination with ATR Inhibition (AZD6738) in Advanced Solid Tumors with HER2 Expression (DASH Trial)
<b>10720</b>	Ib	Phase 1b study of Pidnarulex and Trastuzumab Deruxtecan in patients with HER2 expressing Solid Tumors